We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DOLE:NYSEDole plc Analysis

Data as of 2026-03-29 - not real-time

$14.73

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Technical indicators show the stock trading near its 20‑day SMA (14.73) with the 50‑day SMA at 15.32 and the 200‑day SMA at 14.33, suggesting a neutral to slightly bullish bias. The RSI sits at 46.9 and the MACD histogram is positive, while volume is increasing, reinforcing modest upside momentum. Fundamentally, Dole reports a 9.2% revenue growth year‑over‑year, a trailing PE of 14.6, and a dividend yield of 2.31% with a payout ratio of 33%, indicating decent cash generation. However, the DCF fair value of $4.03 versus the current price of $14.73 points to an overvalued valuation, and the company carries a high debt‑to‑equity ratio of 83% despite positive operating cash flow.
Recent material news highlights a 21% full‑year growth and a 32% Q4 surge driven by export strength and margin expansion, alongside a strategic $140 million divestiture of its fresh vegetables business to sharpen focus. Management targets adjusted EBITDA of $400 million in 2026, underscoring a commitment to improve profitability. Balancing the modest technical upside, solid dividend, and strategic initiatives against valuation concerns and leverage, the stock appears best positioned for a cautious hold with potential upside if earnings momentum sustains.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral technical stance with price near 20‑day SMA
  • Increasing volume supporting short‑term demand
  • High valuation relative to DCF

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of ~9% and margin expansion
  • Strategic divestiture sharpening core focus
  • Targeted $400 M adjusted EBITDA for 2026

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustainable dividend yield of 2.31%
  • Low beta and defensive consumer sector positioning
  • Elevated debt levels limiting upside

Key Metrics & Analysis

Financial Health

Revenue Growth9.20%
Profit Margin0.56%
P/E Ratio14.6
ROE8.71%
ROA3.05%
Debt/Equity82.92
P/B Ratio1.0
Op. Cash Flow$88.7M
Free Cash Flow$68.7M

Technical Analysis

TrendNeutral
RSI46.9
Support$13.96
Resistance$16.07
MA 20$14.73
MA 50$15.32
MA 200$14.33
MACDBullish
VolumeIncreasing
Fear & Greed Index65.98

Valuation

Fair Value$4.03
Target Price$17.50
Upside/Downside18.81%
GradeOvervalued
TypeValue
Dividend Yield2.31%

Risk Assessment

Beta0.30
Volatility20.95%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.